CAR-T Application in hematological malignancy

Xiaoqian Kuang

doi:10.62051/ijphmr.v1n1.09

Authors

Xiaoqian Kuang

DOI:

https://doi.org/10.62051/ijphmr.v1n1.09

Keywords:

CAR-T, CRS, SCR, Acute lymphoblastic leukemia type B (B-ALL)

Abstract

This investigation delves into the multifaceted hurdles inherent in utilizing CAR-T cell therapy to combat hematologic malignancies. It highlights the formidable financial barriers, potential adverse effects, and the quest for sustained therapeutic success. We propose an array of solutions aimed at easing the fiscal strain, refining risk identification, and amplifying therapeutic outcomes. Our strategic approaches encompass the augmentation of CAR-T cell design, the formulation of rigorous risk assessment techniques, and the advancement of sophisticated treatment management protocols. Despite the considerable impediments associated with CAR-T cell therapy, its immense prospective benefit in the realm of hematological malignancy treatment is indisputable. The convergence of technological progress and cross-disciplinary synergy heralds a new era of innovation, holding the promise of optimizing CAR-T cell design and therapeutic avenues, ultimately aspiring to yield safer, more efficacious, and enduring treatment modalities for afflicted individuals.

References

Pang, Y., Hou, X., Yang, C., et al. (2018). Advances in CAR T-cell therapy for tumor treatment. Molecular Cancer, 17 (1), 91.

Litzow, M. R., &Ferrando, A. A. (2015). How I treat T-cell acute lymphoblastic leukemia in adults. Blood, 126 (7), 833-841.

Maude, S. L., Laetsch, T. W., Buechner, J., et al. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. The New England Journal of Medicine, 378 (5), 439-448.

Park, J. H., Rivière, I., Gonen, M., et al. (2018). Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. The New England Journal of Medicine, 378 (5), 449-459.

Davila, M. L., Riviere, I., Wang, X., et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine, 6(224), 224ra25.

Bianca, D. S., Jae, H. P., Darin, S., et al. (2018). Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discovery, 8(8), 958-971.

Barrett, D. M., Teachey, D. T., & Grupp, S. A. (2014). Toxicity management for patients receiving novel T-cell engaging therapies. Current Opinion in Pediatrics, 26(1), 43-49.

Topp, M. S., Gökbuget, N., Stein, A. S., et al. (2015). Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncology, 16(1), 57-66.

Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., et al. (2015). Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology, 33(6), 540-549.

Neelapu, S. S., Locke, F. L., Bartlett, N. L., et al. (2017). Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. The New England Journal of Medicine, 377(26), 2531-2544.

Schuster, S. J., Svoboda, J., Chong, E. A., et al. (2017). Chimeric antigen receptor T cells in refractory B-cell lymphomas.The New England Journal of Medicine, 377(26), 2545-2554.

Zhang WY,Liu Y,Wang Y,et al(2017).Long-term safety and efficacy of CAR-T-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials. Signal Transduction and Targeted Therapy, 2, 17054.

Wang, Y., Zhang, W. Y., Han, Q. W., et al. (2014). Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clinical Immunology, 155(2), 160-175.

Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., et al. (2019). B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. Journal of Clinical Investigation, 129(6), 2210-2221.

Raje, N., Berdeja, J., Lin, Y., et al. (2019). Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.The New England Journal of Medicine, 380(18), 1726-1737.

Xu, J.Chen, L. J., Yang, S. S., et al. (2019). Exploratory trial of a bi-epitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 116(19), 9543-9551.

Hallek, M. (2017). Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. American Journal of Hematology, 92(9), 946-965.

Porter, D. L., Levine, B. L., Kalos, M., et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England Journal of Medicine, 365(8), 725-733.

Riches, J. C., Davies, J. K., McClanahan, F., et al. (2013). T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood, 121(9), 1612-1621.

Hoffmann JM,Schubert ML,Wang L,et al.(2018). Differences in expansion potential of naive chimeric antigen receptor T cells from healthy donors and untreated chronic lymphocytic leukemia patients. Frontiers in Immunology, 8, 1956.